Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis
In this large real-world analysis, apixaban, edoxaban and rivaroxaban, but not dabigatran, were associated with worse survival compared to VKA. These findings, consistent with a few other studies including phenprocoumon, cast profound doubts on the unreflected, general use of NOACs. Randomized trials should assess whether phenprocoumon might actually be superior to NOACs.
Authors
- Ursula Marschall (ORCID: https://orcid.org/0009-0008-2607-8996)
- Joachim Gerß (ORCID: https://orcid.org/0000-0003-3489-683X)
- Andreas Faldum (ORCID: https://orcid.org/0000-0002-2674-8098)
- Christiane M. Engelbertz (ORCID: https://orcid.org/0000-0002-2685-5117)
- Lena Makowski (ORCID: https://orcid.org/0000-0002-4672-1351)
- Jeanette Köppe (ORCID: https://orcid.org/0000-0003-3640-2995)
- Holger Reinecke (ORCID: https://orcid.org/0000-0002-4515-1609)
- Jannik Feld (ORCID: https://orcid.org/0000-0003-1555-9192)
- Stefan Andreas Lange (ORCID: https://orcid.org/0000-0002-7512-6228)
- Eva Freisinger (ORCID: https://orcid.org/0000-0002-4409-3179)
- Günter Breithardt
Institutions
- University Hospital Münster (DE)
- BARMER GEK (DE)
Publication Details
- Journal
- Journal of Internal Medicine
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/joim.20006
- Citations
- 5
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01